NCT04761705View on ClinicalTrials.gov

Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension

PHASE1/PHASE2SuspendedINTERVENTIONAL

Enrollment

70

Participants

Timeline

Start Date

March 10, 2021

Primary Completion Date

March 31, 2025

Study Completion Date

July 31, 2025

Conditions

Ocular HypertensionOpen Angle Glaucoma

Interventions

DRUG

JV-GL1

Experimental Treatment

DRUG

Latanoprost 0.005% Ophthalmic Solution

Active Control

Trial Locations (1)

92663

Eye Research Foundation, Newport Beach

Sponsors

Lead Sponsor

JeniVision, Inc.

All Listed Sponsors

lead

JeniVision, Inc.

INDUSTRY

NCT04761705 - Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension | Biotech Hunter | Biotech Hunter